Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Ultimovacs – Invitation to Business Update on April 17, 2024 | ||
By: GlobeNewswire - 09 Apr 2024 | Back to overview list |
|
NON-REGULATORY PRESS RELEASE Oslo, April 9, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company will host a webcast on April 17, 2024, at 11:00. Ultimovacs’ management will provide a company update emphasizing recent developments and the future potential within the clinical program. The presentation will be followed by a Q&A session. Date: Wednesday, April 17, 2024 The webcast can be accessed live or as a replay. Questions to the management can be sent in advance to ir@ultimovacs.com or during the webcast. ==ENDS== About Ultimovacs Ultimovacs is a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines. The lead cancer vaccine candidate UV1 is an off-the-shelf vaccine directed against human telomerase (hTERT), an antigen present in 85-90% of cancers in all stages of tumor growth. A broad clinical program, with Phase II trials in five cancer indications enrolling more than 670 patients, aims to investigate UV1’s impact in combination with other immunotherapies in multiple cancer types. UV1 is a patented technology owned by Ultimovacs. In addition, Ultimovacs’ adjuvant platform, based on the proprietary Tetanus-Epitope-Targeting (TET) technology, combines tumor-specific antigens and adjuvant in the same molecule and is in Phase I clinical development. The Company is listed on Euronext Oslo Stock Exchange (ULTI). About the UV1 Phase II program The immunotherapeutic cancer vaccine UV1 is investigated in combination with checkpoint inhibitors in patients with various cancer indications with diverse tumor biology. The clinical strategy behind the UV1 Phase II program’s diversity is to evaluate the potential broad applicability of the cancer vaccine when combined with other immunotherapies:
About UV1 The UV1 peptides contain several epitopes, shown to be non-restrictive in terms of (HLA) alleles for presentation. It is, therefore not required to perform HLA pre-screening of patients, which potentially enables broad population utilization of the vaccine. UV1 is administered over three months as eight intradermal injections together with the immune-modulator GM-CSF. For further information, please contact: Carlos de Sousa, CEO Email: carlos.desousa@ultimovacs.com Phone: +47 908 92507 Anne Worsøe, Head of Investor Relations Email: anne.worsoe@ultimovacs.com Phone: +47 90686815 This stock exchange announcement was published by Anne Worsøe, Head of Investor Relations at Ultimovacs ASA, on April 9, 2024 at 20:00CET. |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |